Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 18, 2025 09:25 ET | Source: ARS Pharmaceuticals, Inc.

EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

EURneffy (neffy® in the U.S.) offers a new delivery method for adrenaline in the U.K. for adults and children (>30 kg) living with severe allergic reactions ALK-Abelló A/S, which owns the rights...
May 27, 2025 08:00 ET | Source: ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences

SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect...
May 14, 2025 07:00 ET | Source: ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray)

$7.8 million in total neffy U.S. net product revenue in first quarter of 2025 neffy 1 mg available nationwide for children aged four and older and co-promotion agreement with ALK-Abelló Inc....
May 07, 2025 08:00 ET | Source: ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals’ neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms

The availability of neffy 1 mg extends protection to younger, school-aged children—who make up nearly 23% of people needing epinephrine Visit neffy.com for savings and support programs and pay as...
May 05, 2025 08:00 ET | Source: ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results

SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves...
May 02, 2025 08:00 ET | Source: ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians

Agreement builds on landmark licensing deal between ARS Pharma and ALK-Abelló A/S, which provided ARS Pharma with $145 million upfront and ALK with commercialization rights to neffy in Canada, United...
March 20, 2025 07:00 ET | Source: ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

$7.3 million in total neffy® (epinephrine nasal spray) U.S. net product revenue in 2024 since launch in late September 2024 neffy 1 mg approved by U.S. FDA for children aged four and older and...
March 05, 2025 16:10 ET | Source: ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms

neffy 1 mg is the first and only needle-free epinephrine treatment approved for younger children SAN DIEGO, March 05, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a...
March 03, 2025 16:35 ET | Source: ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences

Company to Host Conference Call on March 20 at 8:30 a.m. ET SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to...
February 20, 2025 19:02 ET | Source: ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients

Approximately five months after launch, the inclusion of neffy on these three additional formularies has expanded access to half of all patients and caregivers managing Type 1 allergic reactions,...